Citations

Clear

16280 citation(s) found for "Yu, David".

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease
Jack, Clifford R. , Barkhof, Frederik , Bernstein, Matt A. , Cantillon, Marc, Cole, Patricia E., DeCarli, Charles , Dubois, Bruno , Duchesne, Simon , Fox, Nick C. , Frisoni, Giovanni B. , Hampel, Harald , Hill, David , Johnson, Keith A. , Scheltens, Philip , Schwarz, Adam J. , Suhy, Joyce, Thompson, Paul M. , Weiner, Michael W. , Foster, Norman L. , Frisoni, Giovanni B. , Mangin, Jean‐François , Sperling, Reisa Anne , DeCarli, Charles , Bernstein, Matt A , Jack, Clifford R , Thompson, Paul M , Barkhof, Frederik , Scheltens, Philip , Fox, Nick C

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 4 | Pages: 474

10.1016/j.jalz.2011.04.007 | PMID 21784356 Get It

BackgroundThe promise of Alzheimer's disease biomarkers has led to their incorporation in new diagnostic criteria and in therapeutic trials; however, significant barriers exist to widespread use. Chief among these is the lack of internationally accepted standards for quantitative metrics. Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging measure in Alzheimer's disease and thus represents the most rational target for an initial effort at standardization.Methods and ResultsThe authors of this position paper propose a path toward this goal. The steps include the following: (1) Establish and empower an oversight board to manage and assess the effort, (2) adopt the standardized definition of anatomic hippocampal boundaries on magnetic resonance imaging arising from the European Alzheimer's Disease Centers–Alzheimer's Disease Neuroimaging Initiative hippocampal harmonization effort as a reference standard, (3) establish a scientifically appropriate, publicly available reference standard data set based on manual delineation of the hippocampus in an appropriate sample of subjects (Alzheimer's Disease Neuroimaging Initiative), and (4) define minimum technical and prognostic performance metrics for validation of new measurement techniques using the reference standard data set as a benchmark.ConclusionsAlthough manual delineation of the hippocampus is the best available reference standard, practical application of hippocampal volumetry will require automated methods. Our intent was to establish a mechanism for credentialing automated software applications to achieve internationally recognized accuracy and prognostic performance standards that lead to the systematic evaluation and then widespread acceptance and use of hippocampal volumetry. The standardization and assay validation process outlined for hippocampal volumetry was envisioned as a template that could be applied to other imaging biomarkers.
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Mattsson, Niklas , Andréasson, Ulf , Batish, Sat Dev, Bernardini, Sergio , Bocchio‐Chiavetto, Luisella , Blankenstein, Marinus A. , Carrillo, María C. , Chalbot, Sonia, Coart, Els, Chiasserini, Davide , Cutler, Neal E., Dahlfors, Gunilla, Duller, Stefan, Fagan, Anne M. , Frisoni, Giovanni B. , Galimberti, Daniela , Hampel, Harald , Handberg, Aase , Heneka, Michael T. , Herskovits, A. Zara , Herukka, Sanna‐Kaisa , Humpel, Christian , Iqbal, Khalid , Kaeser, Stephan A. , Kaiser, Elmar, Kapaki, Elisabeth, Kidd, Daniel, Klivènyi, Péter , Knudsen, Cindy Soendersoe, Kummer, Markus P. , Lui, James, Lladó, Albert , Li, Qiao‐Xin , Martins, Ralph N. , Masters, Colin L. , McAuliffe, John C., Mercken, Marc, Moghekar, Abhay , Molinuevo, José Luís , Montine, Thomas J. , Nowatzke, William, O’Brien, Richard , Otto, Markus , Parnetti, Lucilla , Petersen, Ronald C. , Prvulovic, David, Reus, Herman P.M. de, Scarpini, Elio , Stefani, Alessandro , Schröder, Johannes , Shaw, Leslie M. , Skinningsrud, Anders, Skrogstad, Brith, Spreer, Annette, Trojanowski, John Q. , Tumani, Hayrettin , Umek, Robert M., Broeck, Bianca Van, Vanderstichele, Hugo, Vécsei, László , Blennow, Kaj , Frisoni, Giovanni B. , Persson, Staffan , Arai, Hiroyuki N. , Forlenza, Orestes Vicente , Galasko, Douglas , Holtzman, David M. , Hyman, Bradley T. , Jucker, Mathias , Lewczuk, Piotr , Paraskevas, George P. , Rissman, Robert A. , Soininen, Hilkka S. , Talib, Leda Leme , Teunissen, Charlotte E. , Verbeek, Marcel M. , Windisch, Manfred , Zhang, Jing , Zetterberg, Henrik , Parnetti, Lucilla , Molinuevo, José Luis , Masters, Colin L , Otto, Markus , Galimberti, Daniela

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 4 | Pages: 386

10.1016/j.jalz.2011.05.2243 | PMID 21784349 Get It

BackgroundThe cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)‐42, total‐tau (T‐tau), and phosphorylated‐tau (P‐tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch‐to‐batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.MethodsThe program is open for laboratories using commercially available kits for Aβ, T‐tau, or P‐tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Mölndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples.ResultsForty laboratories participated. Twenty‐six used INNOTEST enzyme‐linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO‐BIA AlzBio3 kit (both measure Aβ‐(1‐42), P‐tau(181P), and T‐tau), and 5 used Meso Scale Discovery with the Aβ triplex (AβN‐42, AβN‐40, and AβN‐38) or T‐tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within‐laboratory precisions differed considerably between biomarkers within individual laboratories.ConclusionsMeasurements of CSF AD biomarkers show large between‐laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers.
Endocrinopathies in the Cardiac ICU
Schwartz, Steven M. , Portman, Michael A. , Crow, Sheri, Nelson, David P. , Anand, Kanwaljeet J. S. , Zimmerman, Jerry J.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | July 25, 2011 | Volume: 2 | Issue: 3 | Pages: 400-410

10.1177/2150135111406941 | PMID 23803992 Get It

The past several years have seen an increased appreciation of the potential role of the endocrine system in the recovery process following surgery for congenital heart disease. Many of the hormonal changes following cardiac surgery are adaptive and necessary, whereas activation of proinflammatory cytokine and chemokine responses and some of the metabolic changes following surgery are likely mediators leading to detrimental outcomes. Additionally, other hormonal perturbations may contribute to adverse outcomes. This review examines the pain and the stress response, thyroid function and hyperglycemia following cardiopulmonary bypass (CPB), and the potential role of corticosteroids in the pediatric cardiac critical care unit.
Assessment of cognition in early dementia
Silverberg, Nina, Ryan, Laurie, Petersen, Ronald C. , Posner, Holly, Hilsabeck, Robin C. , Rizzo, Albert, Ott, Brian R. , Albert, Marilyn S. , Wagster, Molly V., Schinka, John A., Cullum, C. Munro , Farias, Sarah Tomaszewski , Balota, David A., Budson, Andrew E. , Strutt, Adriana M. , Gollan, Tamar H. , Babcock, Debra, Kramer, Joel H. , Carrillo, María C. , Sperling, Reisa Anne , Snyder, Peter J. , Gallagher, Michela , Raber, Jacob , Possin, Katherine L. , King, Jonathan W. , Kaye, Jeffrey , Rao, Stephen M. , Loewenstein, David , Brandt, Jason , Manly, Jennifer J. , Barnes, Lisa L. , Ganguli, Mary , Litvan, Irene , Ferman, Tanis J.

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 3 | Pages: No page available

10.1016/j.jalz.2011.05.001 | PMID 23559893 Get It

Better tools for assessing cognitive impairment in the early stages of Alzheimer's disease (AD) are required to enable diagnosis of the disease before substantial neurodegeneration has taken place and to allow for detection of subtle changes in the early stages of progression of the disease. The National Institute on Aging and the Alzheimer's Association convened a meeting to discuss state‐of‐the art methods for cognitive assessment, including computerized batteries, as well as new approaches in the pipeline. Speakers described research using novel tests of object recognition, spatial navigation, attentional control, semantic memory, semantic interference, prospective memory, false memory, and executive function as among the tools that could provide earlier identification of individuals with AD. In addition to early detection, there is a need for assessments that reflect real‐world situations so as to better assess functional disability. It is especially important to develop assessment tools that are useful in ethnically, culturally, and linguistically diverse populations as well as in individuals with neurodegenerative disease other than AD.
Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
Sobel, Burton E., Hardison, Regina M., Genuth, Saul, Brooks, Maria M. , McBane, Robert D. , Schneider, David J. , Huber, Kurt , Wołk, Robert , Frye, Robert L. , Investigators, for the BARI 2D, Pratley, Richard E. , Krishnaswami, Ashok , Investigators, for the BARI 2D, McBane, Robert , Huber, Kurt

Mayo Clinic

Circulation | July 19, 2011 | Volume: 124 | Issue: 6 | Pages: 695-703

10.1161/circulationaha.110.014860 | PMID 21768545 Get It

Background— Effects were compared in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial of 2 mechanistically different strategies for treatment of hyperglycemia, insulin-sensitizing and insulin-providing strategies, on biomarker profiles reflecting the balance between fibrinolysis and thrombosis and the intensity of inflammation implicated in diabetic vasculopathy. Methods and Results— A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years. Plasminogen activator inhibitor type 1 antigen and activity, tissue plasminogen activator antigen, fibrinogen, D-dimer, C-reactive protein, insulin, and hemoglobin A 1c were assayed in blood samples acquired at baseline and at 12 regular intervals throughout the follow-up interval. Higher baseline D-dimer, fibrinogen, and C-reactive protein portended a poor prognosis in patients in both groups. In contrast to the insulin-providing strategy, the insulin-sensitizing strategy led to (1) lower plasma insulin; (2) lower plasminogen activator inhibitor type 1 antigen and activity and lower tissue plasminogen activator antigen (known to track with plasminogen activator inhibitor type 1); and (3) lower C-reactive protein and fibrinogen at all intervals after baseline ( P <0.001 for each). Conclusions— The insulin-sensitizing treatment strategy led to changes in biomarker profiles indicative of decreased insulin resistance, an altered balance between thrombosis and fibrinolysis favoring fibrinolysis, and diminished intensity of the systemic inflammatory state, factors that have been associated with cardiovascular risk. Clinical Trial Registration— http://www.clinicaltrials.gov . Unique identifier: NCT00006305.
Uveitis-Associated Epitopes of Retinal Antigens Are Pathogenic in the Humanized Mouse Model of Uveitis and Identify Autoaggressive T Cells
Mattapallil, Mary J. , Silver, Phyllis B., Mattapallil, Joseph J. , Horai, Reiko , Karabekian, Zaruhi , McDowell, Jenny, Chan, Chi-Chao, James, Eddie A. , Kwok, William W. , Sen, H. Nida, Nussenblatt, Robert B. , David, Chella S., Caspi, Rachel R

Mayo Clinic

The Journal of Immunology | July 16, 2011 | Volume: 187 | Issue: 4 | Pages: 1977-1985

10.4049/jimmunol.1101247 | PMID 21765017 Get It

Abstract Noninfectious uveitis is a leading cause of blindness and thought to involve autoimmune T cell responses to retinal proteins (e.g., retinal arrestin [soluble-Ag (S-Ag)]). There are no known biomarkers for the disease. Susceptibility is associated with HLA, but little is known about susceptible class II alleles or the potentially pathogenic epitopes that they present. Using a humanized HLA-transgenic mouse model of S-Ag–induced autoimmune uveitis, we identified several susceptible and resistant alleles of HLA-DR and -DQ genes and defined pathogenic epitopes of S-Ag presented by the susceptible alleles. The sequences of these epitopes overlap with some previously identified peptides of S-Ag (“M” and “N”), known to elicit memory responses in lymphocytes of uveitis patients. HLA-DR–restricted, S-Ag–specific CD4+ T cells could be detected in blood and draining lymph nodes of uveitic mice with HLA class II tetramers and transferred the disease to healthy mice. Importantly, tetramer-positive cells were detected in peripheral blood of a uveitis patient. To our knowledge, these findings provide the first tangible evidence that an autoimmune response to retina is causally involved in pathogenesis of human uveitis, demonstrating the feasibility of identifying and isolating retinal Ag-specific T cells from uveitis patients and may facilitate their development as biomarkers for the disease.
Degree of Variability in Performance on Breast Cancer Quality Indicators: Findings From the Florida Initiative for Quality Cancer Care
Gray, Jhanelle E. , Laronga, Christine , Siegel, Erin M. , Lee, Ji‐Hyun , Fulp, William J. , Fletcher, Michelle , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George , Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Shibata, David , Malafa, Mokenge P. , Jacobsen, Paul B. , Markham, Merry J

Mayo Clinic

Journal of Oncology Practice | July 15, 2011 | Volume: 7 | Issue: 4 | Pages: 247-251

10.1200/jop.2010.000174 | PMID 22043190 Get It

The Florida Initiative for Quality Cancer Care has identified how multiple aspects of breast cancer care can be improved.
Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN
Whitwell, Jennifer L. , Weigand, Stephen D. , Gunter, Jeffrey L. , Rademakers, Rosa , Baker, Matt , Petersen, Ronald C. , Jack, Clifford R. , Josephs, Keith A. , Boeve, Bradley F. , Knopman, David S. , Wszołek, Zbigniew K. , Jack, Clifford R

Mayo Clinic

Neurology | July 14, 2011 | Volume: 77 | Issue: 4 | Pages: 393-398

10.1212/wnl.0b013e318227047f | PMID 21753165 Get It

O-021 Hospitalization costs for endovascular and surgical treatment of unruptured cerebral aneurysms in the USA are substantially higher than medicare payments
Brinjikji, Waleed , Kallmes, David F. , Cloft, Harry J. , Lanzino, Giuseppe

Mayo Clinic

Journal of NeuroInterventional Surgery | July 13, 2011 | Volume: 3 | Issue: Suppl 1 | Pages: A9.2-A9

10.1136/neurintsurg-2011-010097.21 Get It

Background and Purpose Endovascular and surgical options are both available for the treatment of unruptured cerebral aneurysms. Knowledge of the costs for hospitalization of these patients is important to understanding economic impact of these patients on hospitals. Methods Using the National Inpatient Sample, hospitalizations for clipping and coiling of unruptured cerebral aneurysms from 2001 to 2008 were identified by cross-matching ICD-9 codes for diagnosis of unruptured aneurysm with procedure codes for clipping or coiling of cerebral aneurysms, and excluding all patients with diagnosis of subarachnoid hemorrhage and intracerebral hemorrhage. Hospital costs for 2008 were correlated with age, gender, and discharge status, and compared to Medicare payments. Results Costs of both clipping and coiling have increased from 2001 to 2008. The median 2008 hospital costs were US$23 574 (IQR 18233–29941) for clipping and US$25 734 (IQR 17436–35846) for coiling without complication, which were higher than the average Medicare payment of US$12 599. The median hospital costs were US$36 188 (IQR 21831–55308) for clipping and US$40 502 (IQR 24289–50108) for coiling treatments complicated by major morbidity, and US$68 165 (IQR 32972–100211) for clipping and US$56 020 (IQR 00000–00000) for coiling treatments complicated by mortality, which were higher than the average Medicare payments for patients with major complications and comorbidities of US$22 946. In multivariate analysis, female gender was associated with higher costs for coiling (p=0.02), and poor discharge status was associated with higher costs for both clipping (p<0.001) and coiling (p<0.001). Conclusions Hospitalization costs for patients undergoing clipping and coiling of unruptured cerebral aneurysms are substantially higher than Medicare payments.